Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes. [GOC:go_curators]
Negative regulation of pinocytosis is a complex cellular process that inhibits the uptake of extracellular fluids and solutes into the cell through small vesicles called pinosomes. It plays a crucial role in maintaining cellular homeostasis, preventing excessive fluid accumulation, and controlling the entry of specific molecules. This process involves a variety of molecular players, including receptors, signaling pathways, and cytoskeletal components.
Here is a detailed description of the biological process:
1. **Initiation:** The process often begins with the activation of specific receptors on the cell surface. These receptors can bind to various ligands, such as growth factors, hormones, or other signaling molecules, triggering the activation of intracellular signaling pathways.
2. **Signaling Cascade:** Upon receptor activation, a cascade of intracellular signaling events ensues. This may involve the activation of protein kinases, phosphatases, or other signaling molecules, leading to changes in protein phosphorylation, protein-protein interactions, and gene expression.
3. **Cytoskeletal Regulation:** The activation of signaling pathways can influence the organization and dynamics of the cytoskeleton. This often involves the regulation of actin filaments, which are crucial for the formation and movement of pinosomes.
4. **Inhibition of Pinocytosis:** The activated signaling pathways can lead to several mechanisms that inhibit pinocytosis:
* **Blockade of Pinocytosis Initiation:** Certain signaling pathways can directly inhibit the formation of pinocytosis vesicles by preventing the assembly of proteins required for vesicle budding.
* **Interference with Actin Dynamics:** Alterations in actin filament organization can hinder the movement and formation of pinosomes, making it difficult for them to pinch off from the cell membrane.
* **Regulation of Pinocytic Machinery:** Signaling pathways can target proteins involved in the formation and function of pinosomes, such as clathrin, dynamin, or other components of the pinocytic machinery, ultimately suppressing their activity.
5. **Termination:** The negative regulation of pinocytosis is often temporary, as cells need to adapt to changing conditions and maintain the necessary balance of fluid and solute uptake. The signaling pathways involved in inhibition eventually shut down, allowing pinocytosis to resume when required.
In summary, negative regulation of pinocytosis is a multi-step process involving complex signaling events, cytoskeletal regulation, and the modulation of pinocytic machinery. This intricate process ensures that the cell maintains its internal environment and controls the uptake of extracellular fluids and solutes.
'"
Protein | Definition | Taxonomy |
---|---|---|
Oxysterols receptor LXR-alpha | An oxysterols receptor LXR-alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13133] | Homo sapiens (human) |
Oxysterols receptor LXR-beta | An oxysterols receptor LXR-beta that is encoded in the genome of human. [PRO:DNx, UniProtKB:P55055] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
4-chlorophenol | 4-chlorophenol : A monochlorophenol substituted at the pare position by a chlorine atom. 4-chlorophenol: used as a root canal irrigant | monochlorophenol | |
butylparaben | organic molecular entity | ||
3-chlorophenol | 3-chlorophenol : A monochlorophenol carrying the chloro substituent at position 3. | monochlorophenol | |
4-phenoxyphenol | phenoxyphenol | ||
bis(4-oxyphenyl)sulfide | 4,4'-thiodiphenol: structure in first source | phenols | |
1-deoxynojirimycin | 1-deoxy-nojirimycin: structure in first source duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite |
betulinic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite | |
25-hydroxycholesterol | 25-hydroxy steroid; oxysterol | human metabolite | |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
3 beta-hydroxy-delta 5-cholenic acid | steroid | ||
podocarpic acid | podocarpic acid : An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position. podocarpic acid: structure | abietane diterpenoid | |
(20s)-20-hydroxycholesterol | 20-hydroxycholesterol : An oxysterol that is cholesterol substituted by a hydroxy group at position 20. 20-hydroxycholesterol: RN given refers to (20S)-isomer | 20-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | human metabolite; mouse metabolite |
24-hydroxycholesterol | (24S)-24-hydroxycholesterol : A 24-hydroxycholesterol that has S configuration at position 24. It is the major metabolic breakdown product of cholesterol in the brain. | 24-hydroxycholesterol | biomarker; human blood serum metabolite; mouse metabolite |
27-hydroxycholesterol | (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration. | 26-hydroxycholesterol | apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent |
cyanidin | cyanidin cation : An anthocyanidin cation that is flavylium substituted at positions 3, 3', 4', 5 and 7 by hydroxy groups. cyanidin: RN given refers to parent cpd; structure | 5-hydroxyanthocyanidin | antioxidant; metabolite; neuroprotective agent |
(22r)-22-hydroxycholesterol | (22R)-22-hydroxycholesterol : An oxysterol that is the 22R-hydroxy derivative of cholesterol. | 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | |
22s-hydroxycholesterol | (22S)-22-hydroxycholesterol : An oxysterol that is the 22S-hydroxy derivative of cholesterol. | 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | |
2-chloro-1,4-dimethoxybenzene | dimethoxybenzene | ||
gw 3965 | GW 3965: a liver X receptor ligand | diarylmethane | |
t0901317 | T0901317: an LXRalpha and LXRbeta agonist | ||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
24,25-epoxycholesterol | 24,25-epoxycholesterol: Rn given refers to (3alpha,5beta)-isomer; structure given in first source 24(S),25-epoxycholesterol : A 3beta-hydroxy-Delta(5)-steroid that is desmosterol in which the double bond at position 24-25 has been oxidised to the corresponding epoxide (the 24S diastereoisomer). It is an oxysterol agonist of the liver X receptor. | 3beta-hydroxy-Delta(5)-steroid; cholestanoid; epoxy steroid | liver X receptor agonist |
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
piericidin a | piericidin A : A member of the class of monohydroxypyridines that acts as an irreversible mitochondrial Complex I inhibitor that strongly associates with ubiquinone binding sites in both mitochondrial and bacterial forms of NADH:ubiquinone oxidoreductase piericidin A: pyridine-substituted fatty alcohol antibiotic; minor descriptor (75-85); on-line & Index Medicus search ANTIBIOTICS (75-85); RN given refers to (S-(R*,R*-(all-E)))-isomer | aromatic ether; methylpyridines; monohydroxypyridine; secondary allylic alcohol | antimicrobial agent; bacterial metabolite; EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor; mitochondrial respiratory-chain inhibitor |
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
acanthoic acid | acanthoic acid: from root bark of Acanthopanax koreanum; structure given in first source | ||
3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid | |||
riccardin c | riccardin C: isolated from liverworts; functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist; structure in first source | ||
bms 687453 | |||
way 252623 | 2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole: a partial LXR agonist | ||
cholenic acid dimethylamide | cholenic acid dimethylamide: binds LXRalpha receptor; structure in first source | ||
incb-018424 | nitrile; pyrazoles; pyrrolopyrimidine | antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | |
glucopiericidin a | glucopiericidin A: from Streptomyces pactum S48727 as co-metabolite of piericidin A(1); structure given in first source; glycoside antibiotic | ||
gsk4112 | GSK4112: a Rev-erbalpha agonist; structure in first source | ||
sr9009 | |||
sr9011 | SR9011: a REV-ERB agonist; structure in first source | ||
sr9238 | SR9238: liver-selective LXR inverse agonist that suppresses hepatic steatosis; structure in first source |